greeksoup/ stocks
Stocks / United States / COR · Wholesale-Drugs, Proprietaries & Druggists' Sundries · NYSE

Cencora, Inc. (COR)

Compare with another name

Cencora, Inc. (COR) reported revenue of $84.8 billion for Q3 FY2026, the quarter ended 30 June 2026, up 5.1% on the same quarter a year earlier. Net income was $764 million, up 11.1% on the year, and diluted earnings per share $3.94. The figures are the company's own, from the 10-Q it filed with the SEC on 5 August 2026.

Revenue$84.8 billionup 5.1%
Net income$764 millionup 11.1%
Diluted EPS$3.94
QuarterQ3 FY2026ended 30 June 2026

Ratios

From the filings

ROE86.0%
ROCE20.6%
Operating margin0.9%
Net margin0.8%
FCF margin1.2%
Interest covern/a
Debt to equity3.84
Cash conversion1.84
Share count, 1 year-1.6%
Sales CAGR, 3 years10.4%
Profit CAGR, 3 years-2.9%
EPS, TTM$13.47

At the close of 21 September 2026

Price$316.49
Market cap$60.4 billion
Stock P/E23.50
Price to book19.80
EV / EBITDA16.99
Dividend yield0.7%
Market cap / sales0.18
52-week high$374.75
52-week low$252.74
Price, 1 year9.1%
Price CAGR, 3 years19.4%
Price CAGR, 5 years21.0%

Every figure is arithmetic on the filed lines (hover a name for the formula); the priced ones use the latest daily close, CBOE delayed quotes, daily history, by CBOE, for splits. Debt to equity here stands on long-term debt as Cencora, Inc. files it, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.

Price, 17 September 2021 to 21 September 2026

Daily closes from CBOE delayed quotes, daily history, by CBOE, for splits; the last is 21 September 2026. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Drawn in your browser; the range and overlay you pick are remembered here only.

The public record on COR

Filings28 in twelve months: 19 current reports (8-K), about 14 regulation fd disclosure; 5 officer or director change; 5 other events; 4 results of operations; 3 material agreement
Planned insider sales19 Form 144 notices in twelve months, $68.5 million; latest 16 September 2026
Options tapeput/call 0.76 by open interest on 23 September 2026; the straddle prices a 5.3% move to 16 October 2026
Holders10 of the followed funds hold it; largest Geode Capital Management; 2 Schedule 13D or 13G filings in twelve months
Insider trading11 sales and 3 purchases on Form 4 in twelve months
Congress3 House trades disclosed in six months
Short interest4.5 million shares short, 4.49 days to cover at 31 August 2026
Documentsthe 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Quarterly results, the last 12 quarters

Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue68,92272,25368,41474,24179,05081,48775,45480,66483,72985,93278,35684,755
Cost of revenue66,66969,78465,87671,83176,55878,92972,39477,75680,77582,86074,76881,148
Gross profit2,2532,4692,5382,4112,4922,5583,0602,9072,9543,0723,5883,607
Gross margin3%3%4%3%3%3%4%4%4%4%5%4%
SG&A1,3941,3991,3891,3831,4901,4721,6001,6731,7491,7951,9782,132
Operating income4778235536721277061,03686818.57601,1431,120
Operating margin1%1%1%1%0%1%1%1%0%1%1%1%
Pre-tax income446783467628125620929896-1877092,089996
Tax rate22%23%10%22%94%20%23%23%n/a20%22%22%
Net income3516024214833.4489718687-3405601,641764
Net margin1%1%1%1%0%1%1%1%-0%1%2%1%
Diluted EPS$1.72$2.98$2.09$2.42n/a$2.50$3.68$3.52-$1.74$2.87$8.40$3.94
Operating cash flow1,827885-8782,4781,000-2,7193,3511093,133-2,3051,3392,654
Capital expenditure17574.2113118182106129183250119166226
Free cash flow1,651811-9912,360818-2,8253,222-74.02,884-2,4251,1732,428
Buybacks27438650.855050538550.00.00.1n/an/an/a
Dividends paid98.3106107103101111111107108127117117
Shares outstanding201m199m199m197m195m194m194m194m194m195m195m191m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Profit and loss, 12 fiscal years and the trailing twelve months

FY2014 FY2015 FY2016 FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025TTM
Revenue119,569135,962146,850153,144167,940179,589189,894213,989238,587262,173293,959321,333332,771
Cost of revenue116,587132,432142,577148,598163,327174,451184,702207,046230,291253,214284,049309,854319,550
Gross profit2,9823,5294,2734,5464,6125,1385,1926,9438,2968,9599,91011,47913,221
Gross margin2.5%2.6%2.9%3.0%2.7%2.9%2.7%3.2%3.5%3.4%3.4%3.6%4.0%
Selling, general and administrative1,5811,9082,0912,1292,4602,6642,7673,5944,8495,3105,6616,4947,654
Operating income7824221,5261,0601,4441,112-5,1352,3542,3662,3412,1752,6293,042
Operating margin0.7%0.3%1.0%0.7%0.9%0.6%-2.7%1.1%1.0%0.9%0.7%0.8%0.9%
Pre-tax income6702691,3919181,177967-5,2942,2222,1832,1612,0042,2583,607
Income tax388407-37.0553-438113-1,894677517428485691967
Effective tax rate57.9%151.4%-2.7%60.3%-37.2%11.7%n/a30.5%23.7%19.8%24.2%30.6%26.8%
Net income274-1381,4283641,658855-3,4091,5401,6991,7451,5091,5542,625
Net margin0.2%-0.1%1.0%0.2%1.0%0.5%-1.8%0.7%0.7%0.7%0.5%0.5%0.8%
Diluted EPS$1.17-$0.62$6.32$1.64$7.53$4.04-$16.65$7.39$8.04$8.53$7.53$7.96$13.47
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

Income statement lines from each year's 10-K, the year linked to its filing; TTM is the sum of the last four quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Cash flow and capital returned

FY2014 FY2015 FY2016 FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025TTM
Operating cash flow1,4633,9203,1781,5041,4112,3442,2072,6672,7033,9113,4853,8754,821
Capital expenditure264232465466336310370438496458487668761
Free cash flow1,1993,6892,7141,0381,0752,0341,8372,2282,2073,4532,9983,2074,060
Free cash flow margin1.0%2.7%1.8%0.7%0.6%1.1%1.0%1.0%0.9%1.3%1.0%1.0%1.2%
Depreciation and amortisation1892493653984654623915056949641,0921,0511,038
Share-based compensation43.160.965.062.262.358.974.499.693.4125148148149
Buybacks7541,8592,26633063967442082.24841,1811,491435n/a
Dividends paid214254288320333339344367392399416437468
Dividend per share$0.94$1.16$1.36$1.46$1.52$1.60$1.66$1.76$1.84$1.94$2.04$2.20n/a
Diluted shares, weighted235m0m226m222m220m212m205m208m211m205m200m195m194m
Shares outstanding at period end222m207m220m218m213m207m204m208m206m201m195m194m191m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

Buybacks and dividends are the cash paid in the year, from the cash flow statement; the dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet at year end

FY2014 FY2015 FY2016 FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025TTM
Total assets21,53227,96333,65635,31637,67039,17244,27557,33856,56162,55967,10276,59083,806
Cash and equivalents1,8092,1672,7422,4352,4933,3744,5982,5473,3882,5923,1334,3562,815
Receivables6,3138,2239,17610,30311,31412,38713,84618,16718,45320,91123,87225,22525,448
Inventory8,5949,75510,72411,46111,91911,06012,58915,36815,55617,45518,99920,49221,030
Goodwill2,9494,1445,9916,0446,6646,7066,7079,0318,5049,5749,31813,67716,515
Total debt, as filedn/a3,493n/an/an/an/an/an/a5,703n/an/an/an/a
Long-term debt1,9963,4934,1873,4421774,1734,1206,6845,7034,7874,3887,66111,723
Long-term debt including finance leases1,9963,493n/a3,4424,310n/an/an/an/an/an/an/an/a
Operating lease liabilitiesn/an/an/an/an/an/a3869468649241,0301,417n/a
Finance lease liabilitiesn/an/an/an/a352321n/an/an/an/an/an/an/a
Shareholders' equity1,9436162,1292,0642,9332,879-1,019223-2125226461,5083,051
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

At the fiscal year end; the TTM column is the latest quarter end. A line the company does not tag under the usual name is left out.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded9.0%11.1%10.4%5.1%
Profit growth, compoundedn/an/a-2.9%38.3%
Return on equity, averagen/a340.1%223.7%103.1%

Compounded growth is the latest fiscal year over the year that many years earlier, annualised; the TTM column is the last four quarters over the four before. Return on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Peers: Wholesale-Drugs, Proprietaries & Druggists' Sundries

CompanyMarket capP/EROEOp. marginSales growth
TTM
Debt to equityDiv. yield
Mckesson Corp. MCK$103.4 billion23.78n/a1.6%8.8%n/a0.4%
Cencora, Inc. COR$60.4 billion23.5086.0%0.9%5.1%3.840.7%
Cardinal Health Inc. CAH$53.1 billion32.54n/a1.0%10.1%n/a0.9%

The names on this site in the same industry (the SEC's SIC description), by market capitalisation. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close.

Filings

FilingPeriodFiledWhere
10-Q30 June 20265 August 2026EDGAR
10-Q31 March 20266 May 2026EDGAR
10-Q31 December 20254 February 2026EDGAR
10-K30 September 202525 November 2025EDGAR
10-Q30 June 20256 August 2025EDGAR
10-Q31 March 20257 May 2025EDGAR
10-Q31 December 20245 February 2025EDGAR
10-K30 September 202426 November 2024EDGAR
10-Q30 June 202431 July 2024EDGAR
10-Q31 March 20241 May 2024EDGAR

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install